Abstract 6841: Genotype-Phenotype Discordance in Hypertrophic Cardiomyopathy with a Pathogenic PKP2 Variant
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.6841 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Jad Daw und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Heritable cardiomyopathies are genetically heterogeneous, creating challenges when genotype and phenotype differ. We present a patient with apical hypertrophic cardiomyopathy (HCM) despite having a pathogenic PKP2 variant classically associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), alongside additional uncertain variation in high-evidence cardiomyopathy genes. Patient Information: Our patient is a 67-year-old woman who initially presented with intermittent palpitations and chest discomfort. She denied syncope, exertional intolerance, or heart failure symptoms. Clinical Findings/Timeline: Initial evaluation showed premature ventricular contractions, a 10-beat run of non-sustained ventricular tachycardia, and an incomplete left bundle branch block. Coronary angiography showed no obstructive coronary disease. Initial cardiac magnetic resonance imaging (CMR) was negative for HCM. After 10 years of follow-up, repeat CMR demonstrated apical hypertrophy and myocardial fibrosis consistent with apical HCM, prompting genetic workup. Diagnostics/Reasoning: Genetic testing identified a pathogenic PKP2 exon 7 deletion, a MYH7 missense variant (c.4816C>T, p.R1606C) classified as a variant of uncertain significance (VUS), and a VCL (c.1621C>G, p.Leu541Val) VUS. Although PKP2 is strongly associated with ARVC, the phenotype remained most consistent with HCM. Serial imaging and ECG showed no right ventricular abnormalities or other features of ARVC. Therapeutic Intervention: The patient was managed with metoprolol and serial imaging/ECG surveillance. Follow-up, Outcomes, Adverse Events: The patient remained stable without sustained ventricular arrhythmias, heart failure, or ARVC/apical aneurysm during 10 years of follow-up. Discussion/Synthesis: This case highlights challenges in interpreting cardiomyopathy testing when multiple variants have differing implications for patients and relatives. PKP2-associated ARVC demonstrates incomplete and variable penetrance, which could explain an incidental finding in the absence of clinical phenotype. The MYH7 VUS has been reported in HCM cohorts and may better explain the phenotype, although evidence remains insufficient for clinical interpretation. Finally, and perhaps most novel, this case adds to emerging reports of PKP2 variation in patients with HCM, raising the possibility that PKP2 may contribute to a broader spectrum of cardiomyopathy than previously recognized.
Conclusion
This case demonstrates the importance of clinically correlating genetic findings with the patient's phenotypic presentation. While cascade evaluation for the PKP2 familial variant is available, clinical surveillance of family members will remain essential for HCM risk stratification. Future segregation studies and gene curation may clarify the relevance of PKP2 variation in HCM.
Zitieren
APA
Daw, J., Saggar, A., Dimitrov, T., Parker, K., & Vallakati, A. (2026). Abstract 6841: Genotype-Phenotype Discordance in Hypertrophic Cardiomyopathy with a Pathogenic PKP2 Variant. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.6841
Vancouver
Daw J, Saggar A, Dimitrov T, Parker K, Vallakati A. Abstract 6841: Genotype-Phenotype Discordance in Hypertrophic Cardiomyopathy with a Pathogenic PKP2 Variant. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.6841
BibTeX
@article{Daw2026,
author = {Daw, Jad and Saggar, Alana and Dimitrov, Theodore and Parker, Katie and Vallakati, Ajay},
title = {Abstract 6841: Genotype-Phenotype Discordance in Hypertrophic Cardiomyopathy with a Pathogenic PKP2 Variant},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.6841}
}
EUVIMED